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Aims Ularitide is a synthetic form of urodilatin, a natriuretic peptide produced in the kidney with vaso-
dilating, natriuretic, and diuretic effects, that offers promise for the management of decompensated
heart failure (DHF). We assessed the efﬁcacy and safety of ularitide in treating patients with DHF.
Methods and results In this Phase II randomized, double-blind, placebo-controlled trial, 221 DHF
patients received either placebo (n ¼ 53) or ularitide at 7.5 ng/kg/min (n ¼ 60), 15 ng/kg/min
(n ¼ 53), or 30 ng/kg/min (n ¼ 55) as a 24-h continuous infusion. At 6 h, ularitide demonstrated a sig-
niﬁcant decrease in pulmonary capillary wedge pressure (P ¼ 0.052, P ¼ 0.000004, P ¼ 0.000002,
respectively) and improved dyspnoea score in the 7.5, 15, and 30 ng/kg/min ularitide group
(P ¼ 0.0026, P ¼ 0.0026, P ¼ 0.0013, respectively). Ularitide reduced systemic vascular resistance
and increased cardiac index for the 15 and 30 ng/kg/min groups (P ¼ 0.017, P ¼ 0.00002, respectively).
Systolic blood pressure (BP) decreased dose dependency. Heart rate and serum creatinine were
unchanged through day 3. Most frequently reported drug-related adverse events through day 3 in all
ularitide groups were dose-dependent BP decrease and hypotension.
Conclusion Ularitide lowered cardiac ﬁlling pressures and improved dyspnoea without apparent early
deleterious effects on renal function in DHF patients. These results suggest that ularitide may play a
role in the management of DHF.
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Introduction
Heart failure (HF) is a major, expanding public health
problem with a poor prognosis and also the most common
cause for hospitalization of elderly patients and accounts
for 60% of treatment costs.1
Ularitide is a synthetic form of urodilatin, a natriuretic
peptide hormone secreted by the kidney.2 The natriuretic
peptide family comprises peptides characterized by a
17-amino-acid ring structure differing in six positions and
varying markedly in amino- and carboxy-terminal amino
acid sequences.3 Whereas C-type natriuretic peptide (CNP)
is secreted by the endothelium, atrial natriuretic peptide
(ANP) and brain natriuretic peptide (BNP) are secreted by
the heart. In healthy volunteers, these molecules regulate
vascular and renal homeostasis4–6 increase vasodilation
and urinary sodium, chloride, and volume excretion7–10
and decrease neurohumoral vasoconstrictor
activation.9,11,12 In contrast to ANP, BNP, and CNP, endogen-
ous urodilatin is synthesized in renal distal tubular cells.
Following luminal secretion, urodilatin binds downstream
natriuretic peptide type A receptors in the inner medullary
collecting duct, regulating renal sodium and water
excretion.
The immediate clinical goal in managing decompensated
heart failure (DHF) is to provide symptom relief and to stabil-
ize the patients’ haemodynamics. Therapeutic options
include diuretics, vasodilators, and positive inotropic
agents; however, each of these options is associated with
clinical limitations.13–16 Data from meta-analyses have
raised concerns of an increased risk of renal deterioration
and mortality in DHF patients administered nesiritide.13–14
Thus, the search for agents that improve DHF signs and symp-
toms and preserve renal function without increasing mor-
tality risk has been an area of ongoing research.
In pilot studies, ularitide demonstrated beneﬁcial effects
in congestive heart failure (CHF)17 and acute DHF (ADHF).18
Bolus injections in ADHF patients stimulated diuresis and
natriuresis and signiﬁcantly reduced pulmonary capillary
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wedge pressure (PCWP) and systemic vascular resistance
(SVR).18 Further, in the SIRIUS I study, 24-h ularitide infusions
reduced PCWP.19 This Phase II study, SIRIUS II, evaluated the
haemodynamic and clinical effects of intravenous (iv) ulari-
tide added to standard therapy in hospitalized DHF patients
with dyspnoea at rest or minimal physical activity.
Methods
Study design
This randomized, double-blind, placebo-controlled study in patients
with DHF was performed in 13 German, two Serbian, and four
Russian centres. Patients were randomized to receive ularitide
(7.5, 15, or 30 ng/kg/min) or placebo as a constant 24-h infusion.
At initiation of the trial, separate randomization lists were gener-
ated for each study centre. Randomization was performed in
blocks with each block comprising eight patient numbers; the stat-
istics department of the clinical research organization was respon-
sible for study management and evaluation. Double-blind study
medication was prepared according to the assignment scheme.
Eligible patients were assigned consecutive random numbers in
the order of their inclusion into the trial.
All patients received standard care, including cardiovascular
medication. During a 5-h period (beginning 3 h before initiating
study drug infusion), iv diuretics, angiotensin-converting enzyme
(ACE) inhibitors, vasoactive drugs, phosphodiesterase (PDE) inhibi-
tors, and new iv administration of dopamine/dobutamine were
excluded. Ongoing dopamine/dobutamine infusions were continued
at a constant dose during this 5-h period. At their discretion, inves-
tigators administered diuretics based on patients’ haemodynamic
and clinical state.
Haemodynamic parameters such as PCWP, right atrial pressure
(RAP), and cardiac output (CO) were measured before, during,
and 2 h after end of the infusion. Before, at 6 h, and at 24 h after
the start of infusion, dyspnoea was assessed independently by the
patient and the investigator and samples of pulmonary artery
blood were taken for assessment of oxygen saturation. Blood
pressure (BP), heart rate (HR), and electrocardiographic (ECG)
status were closely monitored throughout the infusion. Adverse
events (AEs) were recorded, and serum creatinine (SCr) levels
were measured at 260 min, 24, 48, and 72 h after start of dosing
and in case of an AE/serious adverse event (SAE). SAEs and mortality
were monitored through day 30.
Before and at the end of infusion, safety laboratory assessments
(clinical chemistry, haematology, and urinalysis) were performed.
At the end of the 30-day follow-up, the investigator contacted
each patient or the patient’s family doctor to assess rehospitaliza-
tion and mortality.
Administration of study drug
Ularitide (CardioPep Pharma GmbH, Hannover, Germany), supplied
as 1 mg of lyophilized powder containing 10-mg mannitol as an exci-
pient in glass vials, was reconstituted and further diluted with an
aqueous solution of 0.9% NaCl.19 The same procedure was per-
formed for placebo vials containing mannitol only. Medication
vials and prepared infusion solution were not distinguishable by
study personnel.
Patient population
The study enrolled 221 white patients admitted to the hospital for
DHF [cardiac index (CI) 2.5 L/min/m2; mean PCWP] 18 mmHg)
and dyspnoea (at rest or with minimal physical activity).
Immediately before dosing, four patients did not have a PCWP
18 mmHg (1, 2, and 1 in the placebo, 7.5-, and 30-ng ularitide
group, respectively); however, these patients fulﬁlled the inclusion
criteria at –30 min and were included into the analysis due to the
intent-to-treat (ITT) principle. All patients suffered from decom-
pensation of chronic HF due to hypertensive heart disease, coronary
heart disease, or dilative cardiomyopathy evaluated by angiography,
ECHO, ECG ﬁndings, and medical history. All patients gave written
informed consent before entry into the study. Baseline haemo-
dynamic measures were CI, mean of 1.9 L/min/m2; PCWP, mean of
25 mmHg; and ejection fraction, ,40% (95% of patients). Among
the different groups, median interval from time of hospitalization
to start of study-drug infusion ranged from 2 to 3 days. All patients
had right-sided heart catheterization. Exclusion criteria included
de novo DHF, systolic blood pressure (SBP) 90 mmHg, myocardial
infarction within the 4 weeks before study entry, severe stenotic
valvular diseases, SCr .2.5 mg/dL, and cardiogenic shock.
Data of all 221 patients who were randomized to treatment rep-
resented the safety population and were also analysed with group
assignment according to the ITT principle.
Efﬁcacy endpoint assessments
The co-primary endpoints at 6 h were (i) change in PCWP compared
with placebo and (ii) changes in the patient’s self-assessed dyspnoea
score, conducted without direct interaction with the investigator,
compared with placebo.
Haemodynamics
Haemodynamic parameters PCWP, RAP, and CO were determined by
right-sided heart catheterization using a 7F Swan-Ganz thermodilu-
tion catheter. CO measurements at –30 min and immediately before
dosing were not allowed to vary by 15% or more. If variation was
.15% (i.e. in haemodynamically unstable patients and in those
with atrial ﬁbrillation), additional measurements were performed,
whereby care was taken to minimize effects of excessive ﬂuid
intake. When CO variability was ,15%, infusion was started later.
Haemodynamic parameters were then measured at þ30 min; at 1,
2, 4, 6, 8, and 24 h of dosing; and 2 h after the end of dosing
(26 h). CI and SVR were calculated by standard formulas.
Myocardial oxygen consumption (MVO2) was calculated using the
formula of Rooke and Feigl.20
Patient-assessed dyspnoea
At baseline, dyspnoea was assessed as being very severely, severely,
moderately, slightly, or not impaired. At 6 h, patients self-assessed
the relative change of dyspnoea compared with baseline that was
recorded by 7-point Likert scale (minimally, moderately, markedly
worse; unchanged; minimally, moderately, markedly better) as
described earlier.21 Patient-assessed dyspnoea was blinded to
haemodynamic measurement. We attempted to reduce potential
bias by performing dyspnoea self-assessment before haemodynamic
measurements, each assisted by different staff members, and by
prohibiting investigators from discussing these measurements or
assisting patients with completing the symptom evaluation.
Nonetheless, multiple haemodynamic measurements were obtained
before these dyspnoea assessments, which may have biased the
results.
Global clinical status
Changes in global clinical status (GCS) relative to baseline, assessed
by the investigator, were recorded by 7-point Likert scale.21 Here,
speciﬁc symptoms of CHF (i.e. dyspnoea, fatigue) were assessed.
We attempted to reduce potential bias by assessing GCS before
haemodynamic measurements.
Renal parameters
Creatinine clearance (CLCR) was estimated from SCr using the
Cockroft–Gault equation.22 This formula has been validated in
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several studies of CHF and renal dysfunction but is used only if SCr is
measured by the Jaffe´ method.23
N-terminal-proBNP
Plasma concentrations of N-terminal-proBNP (NT-proBNP) were
measured in venous blood using the Elecsys 2010 proBNP
sandwich-immunoassay system (Roche Diagnostics, Mannheim,
Germany) with an analytical range of 20 to 35 000 pg/mL.
Safety endpoint assessments
Enrolled patients were hospitalized and monitored for BP, HR, ECG,
and AEs, the last of which was recorded through 72 h. If SBP
decreased to 80 mmHg, conﬁrmed by a control measurement
within 5 min, the infusion was interrupted and this event was
recorded as an AE. Fluid intake and urine output were documented.
Fluid balance was calculated and adjusted according to cardiac
ﬁlling pressures. A follow-up phone call was made on day 30 for
assessment of SAEs and vital status.
Statistical analysis
All efﬁcacy and safety parameters were described and summarized
by treatment group and time point [n, arithmetic mean, standard
deviation (SD), median, minimum, maximum].
The absolute change from baseline in PCWP was evaluated by
repeated measures mixed effects analysis of covariance, including
baseline as covariate, treatment, and time of assessment as
factors as well as treatment-by-assessment interaction. Patients
within the treatment group were considered random factors. All
differences between treatments were estimated together with a
95% conﬁdence interval. To assess the inﬂuence of the baseline
adjustment, the test was repeated without the baseline covariate
but using the same statistical model.
The statistical interpretation of these data with respect to the
primary endpoint (the change in PCWP at 6 h) followed a hierarchi-
cal test principle: if the overall F-test gave an indication of a global
difference between treatment means (P, 0.05), the active doses
were compared with placebo, starting with the highest dose and
ending if one comparison was assessed with a P-value larger than
0.05. All active doses showing a signiﬁcant difference compared
with placebo were then compared against each other. Because of
the hierarchical test principle, all tests were performed at the
local 5% level and no alpha-adjustment was necessary.
P-values for comparisons between treatments were also derived
for other parameters, and time points of interest for quantitative
parameters using the same methods as described earlier, but
without inspection or interpretation of P-values for the main
effects. These P-values can be interpreted as a descriptive
measure of the strength of evidence, independent of the scale of
measurement, but should not be interpreted as statistical proof of
any actual or assumed differences.
The dyspnoea score and global status were described by fre-
quency tables in terms of counts and percentages. Data were ana-
lyzed by assessor and time point with the Uleman test, a version
of the Mann–Whitney U-test for parameters with a low number of
outcomes. This test is most suited for frequency tables with
ordered categories, whereas the commonly applied Mantel–
Haenszel test does not utilize ordering information. Some categories
were represented with very low frequencies only; so the results
were summarized by showing only the percentages of patients
with scores moderately or markedly better, whereas the Uleman
test took into account all categories.24 The same procedure was
applied to the scores for GCS.
AEs were coded using the MedDRA dictionary. The incidence of each
AE (coded by preferred term) and the number and percentage of sub-
jects experiencing eachweredeterminedwithineach treatment group.
A mean baseline value of 25 mmHg for PCWP was expected in the
speciﬁed patient population. Assuming that treatment with 0, 7.5,
15, or 30 ng/kg/min ularitide would lead to changes of 0, 2.5,
3.75, or 5 mmHg and that such changes would exhibit an SD of
7.0 mmHg, the estimation of sample size for an analysis of variance
procedure with alpha ¼ 0.05, and power ¼ 90%, led to the decision
to enroll about 50 patients per group. The assumed SD is consistent
with the results of Colucci et al.25
Results
Patient enrolment
Between February 2003 and October 2004, 221 patients
were randomized (53 patients in the placebo group, 60 in
the 7.5 ng/kg/min ularitide group, 53 in the 15 ng/kg/min
ularitide group, and 55 in the 30 ng/kg/min ularitide
group), of which 220 were treated with study drug or
placebo over 24 h (Figure 1).
Baseline characteristics
Of the 221 randomized patients, 173 (78.3%) were men and
48 (21.7%) were women. The mean study population age was
61 years. Demographic characteristics were comparable
among the four treatment groups. There were no relevant
differences in age, height, or weight. All subjects were
white (Table 1).
Mean haemodynamics at baseline were comparable
among the different groups with respect to CI, PCWP, and
Figure 1 Study ﬂow diagram and patient disposition.
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EF. Median NT-proBNP levels ranged from 2641 to 3524 pg/
mL between treatment groups. Cardiovascular medical
history was comparable for all four treatment groups.
Fifty-two percent of the patients had ischaemic
cardiomyopathy (ICM) as the primary aetiology of their
CHF (47–57%) (Table 1). Main baseline medication consisted
of diuretics, ACE-inhibitors, beta-blockers, digoxin, and
nitrates (Table 2).
Table 2 Previous and concomitant cardiac medication
Drug
n (%)
Previous medication n (%) Concomitant medication during study drug infusion n (%)
Placebo
(n ¼ 53)
Ularitide (ng/kg/min) Placebo
(n ¼ 53)
Ularitide (ng/kg/min)
7.5 15 30 7.5 15 30
(n ¼ 60) (n ¼ 53) (n ¼ 55) (n ¼ 60) (n ¼ 53) (n ¼ 55)
Diuretics 49 (92.5) 56 (93.3) 50 (94.3) 53 (96.4) 43 (81.1) 51 (85.0) 41 (77.4) 46 (83.6)
Loop diuretics 48 (90.6) 56 (93.3) 46 (88.5) 51 (92.7) 42 (79.2) 51 (85.0) 35 (67.3) 42 (76.4)
iv diuretics 35.8 31.7 30.8 41.8 3.8 5.0 5.8 5.4
Nitrates 25 (47.2) 26 (43.3) 31 (58.5) 21 (38.2) 16 (30.2) 20 (33.3) 19 (35.8) 15 (27.3)
Dobutamine 2 (3.8) 1 (1.7) 4 (7.7) 1 (1.8) 1 (1.9) 0 0 1 (1.8)
Continued at
Baseline
NA NA NA NA 1 (1.9) 1 (1.8)
New administration NA NA NA NA
Dopamine 1 (1.9) 4 (6.7) 5 (9.4) 3 (5.5) 1 (1.9) 1 (1.7) 1 (1.9) 3 (5.5)
Continued at
Baseline
NA NA NA NA 1 (1.9) 1 (1.7) 3 (5.5)
New administration NA NA NA NA 1 (1.9)
Digoxin 22 (41.5) 38 (63.3) 36 (67.9) 37 (67.3) 17 (32.1) 32 (53.3) 30 (56.6) 34 (61.8)
ACE inhibitors 47 (88.7) 50 (83.3) 41 (77.4) 43 (78.2) 46 (86.8) 48 (80.0) 40 (75.5) 40 (72.7)
AT-II-receptor
blockers
2 (3.8) 4 (6.7) 3 (5.7) 4 (7.3) 1 (1.9) 5 (8.3) 3 (5.7) 4 (7.3)
b-blockers 39 (73.6) 49 (81.7) 36 (67.9) 37 (67.3) 35 (66.0) 47 (78.3) 37 (69.8) 33 (60.0)
Spironolactone 27 (50.9) 41 (68.3) 36 (67.9) 36 (65.5) 28 (52.8) 40 (66.7) 37 (69.8) 35 (63.6)
Aspirin 33 (62.3) 35 (58.3) 36 (67.9) 29 (52.7) 32 (60.4) 34 (56.7) 33 (62.3) 27 (49.1)
Warfarin 11 (20.8) 12 (20.0) 10 (18.9) 20 (36.4) 9 (17.0) 10 (16.7) 7 (13.2) 14 (25.5)
AT-II-receptor blockers, angiotensin II receptor blockers; NA, not applicable.
Table 1 Baseline demographics, haemodynamics at enrolment, and medical history
Placebo
(n ¼ 53)
Ularitide (ng/kg/min)
7.5 15 30
(n ¼ 60) (n ¼ 53) (n ¼ 55)
Demographics (mean+ SD)
Age (years) 60.6+ 12.3 59.9+ 13.9 59.8+ 10.8 61.5+ 13.8
Height (cm) 174.1+ 8.9 174.0+ 8.7 173.7+ 10.3 174.1+ 9.4
Weight (kg) 81.0+ 15.6 85.1+ 16.8 83.9+ 18.0 82.7+ 16.3
Male, n (%) 44 (83.0) 50 (83.3) 37 (69.8) 42 (76.4)
Haemodynamics mean+ SD
HR (b.p.m.) 76.4+ 2.5 77.8+ 13.9 75.7+ 11.8 78.5+ 13.7
SBP (mmHg) 127.4+ 19.9 126.1+ 24.6 124.9+ 17.6 123.9+ 21.5
DBP (mmHg) 74.5+ 12.7 78.5+ 13.9 77.3+ 10.6 76.5+ 13.3
CI (L/min/m2) 1.9+ 0.4 1.9+ 0.4 1.9+ 0.3 1.9+ 0.4
PCWP (mmHg) 24.9+ 6.0 24.4+ 6.4 25.7+ 5.8 25.4+ 5.0
Ejection fraction (40%) n (%) 50 (94.3) 57 (95) 52 (98.1) 48 (87.3)
NT-proBNP (pg/mL) (median) 3064 3524 2641 2937
Renal function (mean+ SD)
CLCR (mL/min) 78.3+ 34.1 85.4+ 36.6 79+ 36.0 75.3+ 30.3
Cause of HF n (%)
ICM 28 (52.8) 28 (46.7) 30 (56.6) 28 (50.9)
DCM 17 (32.1) 25 (41.7) 19 (35.8) 19 (34.5)
HHD 8 (15.1) 7 (11.7) 4 (7.5) 6 (10.9)
Diabetes n (%) 16 (30.2) 19 (31.7) 15 (28.3) 29 (52.7)
EF, ejection fraction; DCM, dilated cardiomyopathy; HHD, hypertensive heart disease.
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Primary endpoints
Pulmonary capillary wedge pressure
At 6 h, the primary endpoint, PCWP (Figure 2A), was signiﬁ-
cantly decreased in the two highest ularitide groups com-
pared with placebo. In both the 15 and 30 ng/kg/min
groups, PCWP was signiﬁcantly reduced at 6 h compared
with the 7.5 ng/kg/min group (P ¼ 0.005, P ¼ 0.003,
respectively). There was no difference between the two
highest dose groups (P ¼ 0.943). Changes from baseline for
the 15 and 30 ng/kg/min groups vs. placebo showed signiﬁ-
cant differences (P ¼ 0.031, P ¼ 0.015, respectively) 1 h
after onset of infusion, lasting until 24 h; for 7.5 ng/kg/
min group, these differences (P ¼ 0.008) were ﬁrst evident
at 4 h, lasting until 24 h (P ¼ 0.014) (Figure 2A). In this
analysis, the baseline covariate, treatment and time of
assessment were found to be highly signiﬁcant
(P , 0.0001), whereas there was no treatment-by-
assessment interaction (P ¼ 0.3229).
Figure 2 Haemodynamic parameters for placebo (†) and ularitide 7.5 ng/kg/min (S), 15 ng/kg/min (B), 30 ng/kg/min (O) dose groups. (A) Changes from
baseline in PCWP. (B) Changes in RAP. (C) CI. (D) SVR. (E) SBP. (F) Nt-pro-BNP. *P, 0.05 vs. placebo. **P , 0.01 vs. placebo.
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Patients’ dyspnoea assessment
After 6 and 24 h of infusion, patients assessed dyspnoea and
investigators assessed GCS relative to baseline each. For dys-
pnoea, at 6 h, all three ularitide groups differed signiﬁcantly
from the placebo group (P ¼ 0.0026, P ¼ 0.0026, and
P ¼ 0.0013 for the 7.5, 15, and 30 ng/kg/min ularitide
groups, respectively). More patients in the ularitide groups
assessed their changes in dyspnoea as moderately or markedly
better,whereas the placebo groupmost frequently reportedno
change indyspnoea. Deterioration indyspnoeawas reportedby
only one patient receiving placebo. Furthermore, at 24 h,
more patients receiving ularitide in the three different
dosages reported an improvement of dyspnoea compared
with patients treated with placebo (Figure 3).
Haemodynamic effects
At baseline, RAP was markedly elevated in all groups. At 4 h,
the 15 and 30 ng/kg/min ularitide treatment groups dis-
played decreased RAP compared with placebo (P ¼ 0.008,
P ¼ 0.001, respectively), lasting until 24 h for the 7.5 and
30 ng/kg/min ularitide groups (P ¼ 0.028, P ¼ 0.006,
respectively) (Figure 2B). The mean decrease observed
among the 15 ng/kg/min patients at that time was twice
that of the placebo group but not statistically larger.
In the 15 and 30 ng/kg/min ularitide groups, an increase
in CI was already evident 1 h following start of infusion
(P ¼ 0.013, P ¼ 0.00003, respectively). Throughout the infu-
sion period and 2 h after end of dosing, CI remained elev-
ated in the 30-ng/kg/min group. Ularitide at 15 ng/kg/min
increased CI similarly (P ¼ 0.017, P ¼ 0.008, respectively)
at 6 and 8 h (Figure 2C).
The time course of SVR mirrored that of CI. SVR decreased
1 h after start of dosing in the 15 and 30-ng/kg/min groups
compared with placebo (P ¼ 0.003, P ¼ 0.00009, respect-
ively), lasting through 24 h, except at 4 h for the 15-ng/
kg/min group (P ¼ 0.123) (Figure 2D).
SBP at baseline was 127.4+ 19.9 mmHg (placebo),
126.1+ 24.6 mmHg (7.5 ng/kg/min), 124.9+ 17.6 mmHg
(15 ng/kg/min), and 123.9+ 21.5 mmHg (30 ng/kg/min). A
dose-related decrease in SBP occurred during infusion
(Figure 2E). After the end of infusion, SBP increased again
in the 15 and 30 ng/kg/min ularitide groups. HR at baseline
ranged from 75.5+ 11.8 b.p.m. to 78.6+ 14.0 b.p.m.
among the groups. HR did not change and was not different
among the groups (at þ30 min, 1, 2, 4, 6, 8, 16, 24, and
26 h) with min. and max. mean changes from baseline of
21.0 to 2.0 b.p.m. (placebo), 22.8 to 1.5 b.p.m. (7.5 ng/
kg/min), 21.4 to 2.6 b.p.m. (15 ng/kg/min), 22.2 to
1.8 b.p.m. (30 ng/kg/min) at those time points.
MVO2 was decreased in a dose-dependent manner
(mean changes from baseline in D+ SD in % at 6/24 h):
placebo, –1+ 12.8/2 1.5+ 11.5; ularitide 7.5 ng/kg/min,
–3.4+ 11.9/–4.5+ 13.0; ularitide 15 ng/kg/min, –4.6+
11.3/ to 5.7+ 13.1; ularitide 30 ng/kg/min, –7.6+
11.4/2 5.4+ 19.
GCS assessment
For patients’ GCS, at 6 h, the two highest ularitide groups
differed signiﬁcantly from the placebo group (P ¼ 0.0039,
P ¼ 0.0013 for the 15 and 30 ng/kg/min group, respectively)
(Figure 3).
Previous and concomitant medications
Patients’ baseline previous and concomitant medication is
given in Table 2. Average doses of loop diuretics (furosemide
equivalents) administered during dosing were 99 mg in
placebo and 91 mg, 79 mg, and 115 mg in the 7.5, 15, and
30 ng/kg/min ularitide groups, respectively.
NT-proBNP
At baseline, median plasma NT-proBNP levels were patho-
logically elevated. No change was seen at 6 h in the ularitide
groups vs. placebo (Figure 2F), but plasma NT-proBNP sig-
niﬁcantly decreased in the 15 ng/kg/min group and tended
to decrease also in the 30 ng/kg/min group compared with
placebo at 24 h (P ¼ 0.017).
Renal effects and use of loop diuretics
Mean urine output did not differ signiﬁcantly among all treat-
ment groups and ranged from 1925 to 2309 mL/24 h
(Figure 4A); mean ﬂuid intake was comparable in all treatment
groups (ranging from 1611 to 1855 mL/24 h). During dosing,
loop diuretics tended to be given less frequently in the
15 ng/kg/min group (67.3%) compared with the placebo
group (79.2%). At the end of dosing (24 h), SCr changes from
baseline were not signiﬁcant in all treatment groups except
the 15 ng/kg/min ularitide group, which tended to display
Figure 3 Dyspnoea improvement and global clinical status (GCS) assessment at 6 and 24 h. Summarized patients’ dyspnoea and investigators’s GCS assessments
of ‘moderately better’ or ‘markedly better.’ P-values of tests vs. placebo, considering all scores.
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decreased SCr. At 24 h, CLCR tended to be increased in the
placebo group relative to the ularitide groups while at 48 and
72 h CLCR was decreased with both 7.5 and 30 ng/kg/min
which, however, was also seen for placebo (Figure 4B and C).
Safety
An overview of safety results is given in Table 3. Most AEs
were of mild to moderate intensity. Most frequently
reported drug-related AEs in all ularitide groups were BP
decrease (5.4%), hypotension (5.4%), sweating (4.2%), and
dizziness (3.0%). BP decreases occurred usually 4–12 h
after dosing start; about half were asymptomatic. For two
patients after 7.5, four patients after 15, and seven patients
after 30 ng/kg/min ularitide, infusion was temporarily
interrupted because of decreased SBP to below 80 mmHg.
For the same reason, only one patient in each ularitide
group required permanent discontinuation of study drug.
Time to complete resolution of hypotensions was approxi-
mately 0.5–1 h in most cases and lasted up to 4 h in four
cases and 8 h in two cases. All patients recovered comple-
tely either by discontinuation of ularitide infusion or by
elevation of legs and saline infusion.
Transiently decreased HR or bradycardia was reported for
three patients in the 7.5-ng/kg/min group (5%), for one
patient (1.8%) in the 30-ng/kg/min group, but for none in
the 15-ng/kg/min and placebo groups. Although not
reported in the placebo and 7.5-ng/kg/min group, increased
HR or ventricular tachycardia occurred in two patients of the
15-ng/kg/min group (3.8%). Tachyarrhythmia was reported
in one patient in the 30-ng/kg/min group (1.8%).
A total of 12 patients died during the study through day
30 (Table 3): seven patients (13.2%) in the placebo group,
two patients (3.4%) in the 7.5-ng/kg/min group, two
patients (3.8%) in the 15-ng/kg/min group, and one
patient (1.8%) in the 30-ng/kg/min group. Of the seven
placebo patients, ﬁve patients died between day 1 and 8,
two patients between day 19 and 26. All placebo patients
died of HF. Of ﬁve patients in the ularitide group, one
patient died at day 1, and four patients died between
day 11 and 13; three patients of HF and two patients of per-
forated duodenal ulcer and gastric bleeding. More patients
had SAEs in the placebo group compared with the ularitide
groups in both the day 1–3 and day 4–30 time periods
(Table 3).
Median hospitalization time was shorter for the 15 and
30-ng/kg/min groups (122 and 158 h, respectively) com-
pared with 201 and 192 h for placebo and 7.5 ng/kg/min
groups, respectively; this difference was not statistically sig-
niﬁcant and requires further evaluation with larger numbers
of patients.
Discussion
In the SIRIUS II trial, the synthetic natriuretic peptide ulari-
tide signiﬁcantly reduced PCWP and improved dyspnoea in
patients with DHF when added to standard therapy.
Ularitide exerted expected dose-dependent decreases in
BP, as seen also for other vasodilators.21,25–27 These results
suggest that ularitide administered to DHF patients is clini-
cally and haemodynamically active, without apparent dele-
terious effects on short-term renal function.
The favourable haemodynamic effects of ularitide were
sustained through the end of the 24-h infusion period.
These data show that ularitide infusion promptly and con-
sistently lowers cardiac ﬁlling pressures and also leads to a
decrease in MVO2, a favourable effect in ICM.
An additional aim of the trial was to investigate changes in
dyspnoea, a cardinal symptom in patients with DHF.
Compared with placebo, patients receiving ularitide in all
three dose groups reported more moderate and marked dys-
pnoea improvements after 6 and 24 h of infusion. These data
support the ﬁndings of the pilot SIRIUS I study in which a
similar trend was seen in a smaller number of patients.19
Although the dyspnoea scoring assessment used in SIRIUS II
is not validated, it has been commonly used in previous
studies.21 Patient’s self-assessment may be affected by con-
founding variables (e.g. if the patient has a right-sided heart
Figure 4 Renal parameters at 24, 48, and 72 h. (A) Urine output over 24 h.
(B) Changes in SCr. (C) Changes in CLCR; mean+ SEM.
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catheter in place or if haemodynamic parameters are
known). In this trial, we attempted to reduce potential
bias by performing dyspnoea self-assessment before haemo-
dynamic measurements and by prohibiting investigators
from discussing these measurements or assisting patients
with completing the symptom evaluation. Also, in the
placebo group treated with standard care, reduction of
PCWP and an increase in CI were seen; however, it cannot
be excluded that knowledge of the degree of PCWP
reduction by the nursing and medical staff still might have
indirectly affected a patient’s self-assessment.
As a secondary endpoint, investigator-assessed patient
GCS revealed an improvement in the two highest dose
groups at 6 h, which lasted until 24 h in the 15-ng/kg/min
group, thus supporting ularitide’s beneﬁcial effect on clinical
outcome. However, compared with dyspnoea less patients
reported an improvement in GCS, which was also reported
elsewhere.21 Even though assessment was performed
before haemodynamic measurements, it cannot be excluded
that the investigators’ assessment could have been some-
what inﬂuenced by known haemodynamic parameters.
Reduced cardiac ﬁlling pressures that lower ventricular
wall stress during ularitide infusions are also reﬂected in
decreased plasma NT-proBNP concentrations. In contrast to
placebo, where an increase in plasma NT-proBNP was
detected, the two higher ularitide doses decreased
NT-proBNP at 24 h, but the decrease was signiﬁcant for
only the 15 ng/kg/min ularitide group. Notably, the
response of NT-proBNP was not seen at 6 h but was clearly
evident at 24 h. Reductions in right and left ventricular
ﬁlling pressures may result in a reduction of NT-proBNP
with a time lag phase,28 as shown in a smaller number of
patients in the SIRIUS I study.19 NT-proBNP secretion is con-
trolled at the transcriptional level, usually requiring a
longer-term stimulus.29 Therefore, abrupt reductions in
right and left ventricular ﬁlling pressures might not directly
result in a reduction of NT-proBNP as an intermediate bio-
marker. The half-life of NT-proBNP is about 120 min,
suggesting that haemodynamic changes could be reﬂected
by this test approximately every 12 h.29
Renal function frequently deteriorates during treatment
of patients hospitalized for HF, and minor increases in SCr
are independently predictive of worsened outcome.30
Therefore, agents that improve haemodynamics, leading to
beneﬁcial clinical effects but not deteriorating renal func-
tion, are needed for DHF treatment. Ularitide is known to
induce renal effects such as diuresis and natriuresis in
healthy volunteers.9 Among the four treatment groups,
there was no relevant difference in urine output over 24 h
with comparable ﬂuid intake, possibly because of downregu-
lation of the natriuretic peptide A receptor (NPR-A) in CHF31
or upregulation of neutral endopeptidase (NEP 24.11), an
enzyme known to cleave natriuretic peptides. The latter
mechanism was reported to be restricted to the kidneys of
HF models,32 which would explain the prominent haemo-
dynamic and the lack of renal responsiveness to ularitide
infusion. In addition, mild diuretic effects of ularitide may
have been overshadowed by the stronger effects of loop
diuretics given during dosing in a range of 91 to 115 mg in
the different groups. Compared with placebo, 7.5, and
30-ng/kg/min groups, SCr levels tended to be decreased
and CLCR tended to be less decreased in the 15-ng/kg/min
group through 72 h. Taken together, the current data demon-
strate no evidence of deleterious renal effects induced by
ularitide during the infusion and the 2-day follow-up
period. Recent data from a meta-analysis raised concern
about increased risk of renal deterioration in DHF patients
administered nesiritide,13 whereas in the VMAC trial no
such increases were reported through 30 days.21 Also a
recent study reported beneﬁcial effects of nesiritide on post-
operative renal function, however, in patients undergoing
cardiothoracic surgery.33 In SIRIUS II short-term renal
Table 3 Adverse Events
Placebo
(n ¼ 53)
Ularitide (ng/kg/min)
7.5 15 30
(n ¼ 60) (n ¼ 53) (n ¼ 55)
Subjects with any AE day
1–3 n (%)
11 (20.8) 17 (28.3) 13 (24.5) 24 (43.6)
Subjects with any drug-related AE day 1–3 n (%) 4 (7.5) 10 (16.7) 7 (13.2) 11 (20.0)
Subjects with BP decrease/hypotension day
1–3 n (%)
2 (3.8) 5 (8.3) 7 (13.2) 9 (16.4)
Subjects with BP decrease/hypotension during
infusion n (%)
1 (1.9) 5 (8.3) 6 (11.3) 9 (16.4)
Symptomatic 1 (1.9) 4 (6.7) 3 (5.7) 4 (7.3)
Asymptomatic 0 (0) 1 (1.7) 3 (5.7) 5 (9.1)
Subjects with infusions discontinued/interrupted due
to SBP ,80 mmHg n (%)
Temporarily interrupted 0 (0) 2 (3.3) 4 (7.5) 7 (10.9)
Permanently discontinued 0 (0) 1 (1.7) 1 (1.9) 1 (1.8)
Subjects with any SAE n (%)
Day 1–3 2 (3.8) 1 (1.7) 2 (3.8) 1 (1.8)
Day 4–30 7 (13.2) 4 (6.7) 3 (5.7) 5 (9.1)
Deaths n(%)
Day 1–3 2 (3.8) 0 (0) 0(0) 1 (1.8)
Day 4–30 5 (9.4) 2 (3.3) 2 (3.8) 0 (0)
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effects of ularitide were investigated and therefore prospec-
tive trials with longer follow-up periods to investigate the
long-term effects of ularitide on renal function are needed.
The most common drug-related AEs were hypotension and
BP decrease. Patient baseline BPs in this study were compar-
able with those of DHF patients in other studies and regis-
tries.21,34 If a patient was symptomatic, symptoms
developed over several hours and were usually mild.
Hypotension occurred at similar incidence rates with other
vasodilators, including ANP,26 nesiritide, or nitroglycerin
administered in HF patients.21,25,27 In the present study,
cardiac arrhythmias, including bradycardia or tachycardia,
occurred at low incidence rates, were transient, and
resolved completely. In an earlier study, ularitide caused
bradycardia and severe hypotension in one patient with
CHF.35 There was no major adverse safety signal with
regard to mortality rate in the ularitide groups compared
with placebo.
This study has potential limitations. In particular, bias may
be introduced by the use of patient-assessed dyspnoea
scores if the PCWP is possibly known by either the patient
or the observer. In addition, in future studies, AEs and
renal function data should be collected after hospitalization
to investigate longer term adverse outcomes.
The SIRIUS II trial demonstrated that a 24 h infusion of
ularitide at all three doses in patients with DHF resulted in
prompt, consistent lowering of PCWP and LV pump function
improvement associated with improvements in dyspnoea.
Further, ularitide did not impair renal function during the
evaluation period. We conclude that ularitide has potential
for the treatment of patients with DHF, and future studies
with this promising agent are warranted.
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